

Headquarters: Munich, Germany
Product: deepeye® TPS — AI therapy-planning support for retinal diseases (CE marked Class IIa)
Founded: 2021
Founders / Execs: Manuel Opitz (CEO, Co‑Founder); Ratko Petrovic (CTO, Co‑Founder)
Employee count: 11
Known funding: Seed round announced Nov 7, 2023; lead investor YZR Capital; amount undisclosed
Ophthalmology — therapy planning for retinal diseases (e.g., nAMD).
2021
Medtech / Medical Software
Participating investors reported to include Springboard Health Angels, Bayern Kapital and Arve Capital; amount undisclosed/obfuscated in public profiles.
“Has institutional and angel backing (YZR Capital lead; Springboard Health Angels, Bayern Kapital, Arve Capital participated)”
| Company |
|---|